FDA Guidance for Industry: Residual Drug in Transdermal and Related Delivery Systems

Title:
FDA Guidance for Industry: Residual Drug in Transdermal and Related Delivery Systems
Origin/Publisher:

FDA, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM220796.pdf

Content:
This guidance provides recommendations to developers and manufacturers of transdermal drug delivery systems (TDDS), transmucosal drug delivery systems (TMDS), and topical patch products regarding use of an appropriate scientific approach during product design and development

Go back